The U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma
On May 27, 2022 the U.S. Food and Drug Administration (FDA) announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This is the third chimeric antigen receptor (CAR) T cell therapy approved for FL.
“The approval of kymriah offers patients with relapsed or refractory follicular lymphoma a new treatment option and new hope for improving patient outcomes,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “Having this single infusion treatment option helps to transform the way healthcare providers approach this type of blood cancer and we commend those who have contributed to the acceleration of scientific research for the benefit of patients.”
For more information on the FDA approval of tisagenlecleucel (Kymriah), visit the FDA’s website. To learn more about FDA approvals for FL visit lymphoma.org/flfdaupdates.
CAR T Cell Therapy
CAR T cell therapy provides engineered molecules called chimeric antigen receptors (CARs) that recognize and destroy antigens present on the surface of lymphoma cells.